Alnylam Pharmaceuticals (NASDAQ:ALNY) Issues Quarterly Earnings Results, Misses Estimates By $0.16 EPS

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Rating) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($2.00) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.84) by ($0.16), MarketWatch Earnings reports. Alnylam Pharmaceuticals had a negative net margin of 101.01% and a negative return on equity of 109.21%. The company had revenue of $186.90 million for the quarter, compared to analyst estimates of $242.82 million. During the same period in the previous year, the firm posted ($1.71) earnings per share. The firm’s revenue for the quarter was up 37.6% compared to the same quarter last year.

Shares of Alnylam Pharmaceuticals stock traded down $9.73 on Friday, hitting $133.43. 1,428,580 shares of the company’s stock traded hands, compared to its average volume of 804,370. The firm’s 50-day moving average price is $160.27 and its two-hundred day moving average price is $166.57. The company has a debt-to-equity ratio of 1.15, a current ratio of 4.04 and a quick ratio of 3.91. The stock has a market capitalization of $16.11 billion, a PE ratio of -17.81 and a beta of 0.85. Alnylam Pharmaceuticals has a one year low of $125.00 and a one year high of $212.00.

In related news, Director Steven M. Paul sold 15,000 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, April 1st. The stock was sold at an average price of $170.69, for a total transaction of $2,560,350.00. Following the completion of the sale, the director now directly owns 1,000 shares of the company’s stock, valued at $170,690. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 1.40% of the stock is owned by company insiders.

Institutional investors have recently bought and sold shares of the company. JustInvest LLC boosted its stake in Alnylam Pharmaceuticals by 17.9% during the 4th quarter. JustInvest LLC now owns 2,889 shares of the biopharmaceutical company’s stock worth $490,000 after acquiring an additional 438 shares during the last quarter. California State Teachers Retirement System boosted its position in shares of Alnylam Pharmaceuticals by 2.1% during the fourth quarter. California State Teachers Retirement System now owns 209,732 shares of the biopharmaceutical company’s stock worth $35,566,000 after purchasing an additional 4,340 shares in the last quarter. Allstate Corp boosted its position in shares of Alnylam Pharmaceuticals by 102.3% during the fourth quarter. Allstate Corp now owns 10,859 shares of the biopharmaceutical company’s stock worth $1,841,000 after purchasing an additional 5,490 shares in the last quarter. Amalgamated Bank grew its holdings in shares of Alnylam Pharmaceuticals by 52.4% in the 4th quarter. Amalgamated Bank now owns 10,478 shares of the biopharmaceutical company’s stock valued at $1,777,000 after buying an additional 3,602 shares during the period. Finally, Sei Investments Co. increased its position in shares of Alnylam Pharmaceuticals by 5.7% in the 4th quarter. Sei Investments Co. now owns 25,441 shares of the biopharmaceutical company’s stock valued at $4,418,000 after buying an additional 1,379 shares in the last quarter. Institutional investors own 90.64% of the company’s stock.

Several analysts recently commented on ALNY shares. Piper Sandler raised Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $181.00 to $208.00 in a research note on Monday, January 3rd. Stifel Nicolaus restated a “buy” rating and issued a $215.00 target price on shares of Alnylam Pharmaceuticals in a research note on Thursday, March 24th. StockNews.com started coverage on shares of Alnylam Pharmaceuticals in a research report on Thursday, March 31st. They set a “hold” rating for the company. HC Wainwright boosted their price target on shares of Alnylam Pharmaceuticals from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Tuesday, April 12th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $200.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, February 11th. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $218.00.

About Alnylam Pharmaceuticals (Get Rating)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

Recommended Stories

Earnings History for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.